First patients completed the amblyopia phase 2a study

In 2011, Hermo Pharma Ltd. initiated a phase 2a study to test its HER-801 therapeutic concept for treatment of amblyopia in adult patients. First patients have now completed the study, including the 2-month follow-up period after the successful completion of the treatment period. No serious adverse events have been reported so far and most of the reported mild adverse events appear not be related to the study treatment.

The study is designed as a double-blinded, placebo-controlled, multi-center trial to test improvement in visual acuity using Hermo Pharma’s HER-801 combination therapy that includes fluoxetine as the active drug substance. The therapeutic concept is based on prof. Eero Castrén’s and prof. Lamberto Maffei’s (see Scientific Advisory Board) previous preclinical findings suggesting that fluoxetine can restore neuronal plasticity in the adult visual cortex, allowing recovery from amblyopia in adults.